LUYAN PHARMA CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.75 CNY | +1.27% |
|
-0.34% | -2.67% |
| May. 08 | Luyan Pharma Co.,Ltd. Approves Cash Dividend for the Year 2023 | CI |
| Apr. 15 | Luyan Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,426 | 2,664 | 3,081 | 3,034 | 3,236 | 3,493 |
| Enterprise Value (EV) 1 | 4,376 | 5,562 | 5,994 | 7,105 | 7,723 | 7,744 |
| P/E ratio | 13.4 x | 10.4 x | 10.7 x | 9.89 x | 9.36 x | 9.56 x |
| Yield | 1.58% | 1.84% | 2.52% | 3.84% | 3.6% | 3.34% |
| Capitalization / Revenue | 0.21 x | 0.18 x | 0.2 x | 0.17 x | 0.17 x | 0.18 x |
| EV / Revenue | 0.38 x | 0.37 x | 0.39 x | 0.4 x | 0.4 x | 0.39 x |
| EV / EBITDA | 10.5 x | 10.1 x | 10 x | 10.8 x | 10.2 x | 10.3 x |
| EV / FCF | -20.4 x | -5.91 x | -15.4 x | -8.05 x | -39.5 x | 18.9 x |
| FCF Yield | -4.91% | -16.9% | -6.51% | -12.4% | -2.53% | 5.29% |
| Price to Book | 1.55 x | 1.49 x | 1.32 x | 1.22 x | 1.19 x | 1.19 x |
| Nbr of stocks (in thousands) | 326,830 | 326,830 | 388,517 | 388,517 | 388,517 | 388,517 |
| Reference price 2 | 7.424 | 8.150 | 7.930 | 7.810 | 8.330 | 8.990 |
| Announcement Date | 4/18/19 | 4/29/20 | 4/27/21 | 4/25/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 11,501 | 15,009 | 15,531 | 17,545 | 19,463 | 19,846 |
| EBITDA 1 | 415.2 | 551.2 | 597.5 | 657.7 | 756.3 | 752 |
| EBIT 1 | 381.2 | 510.1 | 551 | 604.4 | 702.4 | 694.9 |
| Operating Margin | 3.31% | 3.4% | 3.55% | 3.44% | 3.61% | 3.5% |
| Earnings before Tax (EBT) 1 | 259.8 | 344.1 | 372.1 | 415.2 | 466 | 469.4 |
| Net income 1 | 180.3 | 255.9 | 267.5 | 305.9 | 345.2 | 363.5 |
| Net margin | 1.57% | 1.7% | 1.72% | 1.74% | 1.77% | 1.83% |
| EPS 2 | 0.5529 | 0.7800 | 0.7400 | 0.7900 | 0.8900 | 0.9400 |
| Free Cash Flow 1 | -214.7 | -941 | -390.5 | -882.6 | -195.4 | 409.7 |
| FCF margin | -1.87% | -6.27% | -2.51% | -5.03% | -1% | 2.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 54.48% |
| FCF Conversion (Net income) | - | - | - | - | - | 112.7% |
| Dividend per Share 2 | 0.1176 | 0.1500 | 0.2000 | 0.3000 | 0.3000 | 0.3000 |
| Announcement Date | 4/18/19 | 4/29/20 | 4/27/21 | 4/25/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 |
|---|---|---|
| Net sales 1 | - | 4,751 |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 109.2 | - |
| Net margin | - | - |
| EPS | 0.2800 | - |
| Dividend per Share | - | - |
| Announcement Date | 8/8/23 | 10/23/23 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1,950 | 2,898 | 2,913 | 4,071 | 4,486 | 4,252 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.695 x | 5.257 x | 4.876 x | 6.19 x | 5.932 x | 5.654 x |
| Free Cash Flow 1 | -215 | -941 | -390 | -883 | -195 | 410 |
| ROE (net income / shareholders' equity) | 11.5% | 14.5% | 12.5% | 12.2% | 13.1% | 12.6% |
| ROA (Net income/ Total Assets) | 4.25% | 4.69% | 4.31% | 4.07% | 4.03% | 3.68% |
| Assets 1 | 4,240 | 5,462 | 6,204 | 7,515 | 8,561 | 9,868 |
| Book Value Per Share 2 | 4.800 | 5.480 | 6.020 | 6.410 | 7.000 | 7.580 |
| Cash Flow per Share 2 | 1.580 | 1.310 | 1.530 | 1.070 | 1.530 | 1.560 |
| Capex 1 | 134 | 199 | 171 | 243 | 328 | 529 |
| Capex / Sales | 1.16% | 1.33% | 1.1% | 1.39% | 1.68% | 2.67% |
| Announcement Date | 4/18/19 | 4/29/20 | 4/27/21 | 4/25/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.67% | 469M | |
| +23.03% | 74.04B | |
| -1.52% | 24.18B | |
| +3.67% | 8.46B | |
| +8.55% | 8.34B | |
| -23.71% | 7.64B | |
| +15.20% | 5.33B | |
| -6.90% | 3.92B | |
| +2.68% | 4.12B | |
| +5.56% | 3.89B |
- Stock Market
- Equities
- 002788 Stock
- Financials Luyan Pharma Co.,Ltd.
